Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Babies born at 34 weeks of pregnancy or later who have been diagnosed with persistent pulmonary hypertension of the newborn (a condition where blood pressure in the lungs remains high after birth)
- Babies born at 34 weeks of pregnancy or later who are healthy and have no known conditions (these babies may be included as a comparison group)
Who may not be able to join:
- Babies diagnosed with a birth defect that is considered life-threatening
- Babies with structural problems with the heart at birth, except for two common newborn heart conditions (a small vessel connection between the heart and lungs that normally closes after birth, or a small opening between the two sides of the heart that also normally closes after birth)
- Babies with a physical abnormality in the digestive tract that could affect how the first bowel movement passes through
- Babies born with certain specific birth defects, including a condition where abdominal organs move into the chest (diaphragmatic hernia), a condition affecting kidney and lung development (Potter's syndrome), or underdeveloped lungs (pulmonary hypoplasia)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: G. Ganesh Konduri, MD, Medical College of Wisconsin
Phone: 414-266-6820
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.